Post Menopausal Dryness in the Intimate Area of WomenPhase 2NCT02162160
Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women
A Phase 2 study testing probiotic creme in people with Post Menopausal Dryness in the Intimate Area of Women, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. Read more about this study
- Who is it for?
- Ages 45 to 65 years, women only
- Conditions the study is for
- Post Menopausal Dryness in the Intimate Area of Women
- What is being tested?
- probiotic creme
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 1 siteSweden
- Study dates
- Sep 2013to Mar 2014
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- healthy women 45-65 years old
- with subjective dryness in the intimate area
- postmenopausal with last menstruation more than or equal to 3 years prior to entering the study
- being willing to abstain sexual intercourse during the study period
Who cannot join
- yeast infection or bacterial vaginosis
- use of antibiotics or antifungals
- use of estrogen
- participation in Another study
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Dept of Obstetrics and Gynecology, Dnderyds Hospital
Stockholm, 18288
About this study
Official title: Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women
Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before use of the crème and at the end of a 10 days crème-usage (day 8-10), as well as 10 days after (9-11 days) finished crème-usage.
The hypothesis is that lactobacilli can survive in the intimate area of postmenopausal women with use of a probiotic creme.
Read the detailed description
The rational for using probiotics is that the humans are colonized by a numbers of microorganisms from birth. These microorganisms are the natural flora of the human body. This bacterial ecology may be imbalanced due different circumstances: excessive hygiene, use of antibiotics or other drugs, use of alcohol, smoking, stress, diabetes and many other factors. The natural bacterial flora in the external part of the genital tract might be promoted by help of intimate products containing probiotics.
The study objectives Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before and at the end of a 10 days crème-usage (day 8-10), as well as 10 (9-11) days after finished crème-usage.
The primary endpoint of the study Presence of at least one LN bacteria strain in the intimate area of women in the intervention group compared to the intimate area of women in the control group at the end of a 10 days crème-usage (Day 8-10), as well as 10 (9-11) days after finished crème-usage. The primary endpint will be measured by bacterial Culture.
None-parametric statistical analyses.
Secondary endpoints Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).
Obtain information about the subjective feeling of dryness and freshness in the intimate of women before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).
Only descriptive statistics.
Blinding The active and comparative test product will be filled into white tubes with identical appearance.
The study will be conducted with double-blind design when neither the personnel at the clinic and the participants knows which product they are submitted/received. The study will also be blinded for the laboratory personnel analyzing the samples.
Randomization procedure The women will be randomly assigned to active or comparative test products. Based on a computer-generated list, before start of the study, nine tubes containing Probiotic Intimate Crème (the active product) and 9 tubes containing Soothing crème (the control product) will be randomly assigned to a number between 1 to 18, and the tubes labeled with the numbers. The numbered but otherwise visually identical tubes will delivered to the clinic before start of the study.
During the first visit, the participants will receive a tube consecutively in numerical order, as they are included in the study, i.e. according to their participant number.
The computer-generated randomization list and the product labeling will be carried out by people who don't have direct contact with the study participants.
Sample collection
Vaginal samples:
The samples will be taken by rolling sterile swabs over the upper third part of the lateral vaginal wall.
Labial samples:
For labial sampling, on the left side of the vulva near the vaginal orifice, the labia minor and major will be held apart and a sterile swab will be gently rubbed back and forth five times during rotation. The labial examination area will be approximately 2 cm2.
The swabs will then be placed in a prepared transport medium and sent to laboratory for analyses.
6.12. Study outline
Visit 1:
- Women visiting the clinic will be recruited to the study. After obtained information (Appendix 1) and signed informed consent the women will be clinically examined for any clinical symptoms of Candida vaginitis (ocular examination) and bacterial vaginosis (Amsel's criteria). The dryness of the mucus membranes will be also examined and the vaginal pH measured using a pH-stick.
- Women fulfilling the inclusion criteria will be randomized to 10 days use of test product (Probiotic Intimate Crème) or control product (Soothing Cream, ACO); 2 times daily, every morning and evening at bed time.
- The women will receive detailed instructions about how to use the study products.
- They will also asked to return the empty tube or remaining product at the end of study (Visit 3)
- The women will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale.
- Samples with sterile swabs will be collected from vagina, labia and perineum (Sample 1-L, Sample 1-V) and sent to an independent laboratory for analyses.
Visit 2:
- The 8th-10th day of the intimate crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH.
- They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
- Vaginal and labial swabs will be collected (Sample 2-L, Sample 2-V) and send to an independent laboratory for analyses.
Visit 3:
- 9-11 days after the 10 days crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH measured.
- They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
- Vaginal and labial swabs will be collected. (Sample 3-L, Sample 3-V) and sent to an independent laboratory for analyses.
During each visit, data will be recorded in the CRF.
- Being tested
- probiotic creme, Placebo
- Keywords
- probiotic, post-menopausal, atrophic vaginitis
- Medical subject headings
- Atrophic Vaginitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
probiotic cremeDevice
Also called Ellen AB
Probiotic creme applied
PlaceboDrug
Creme without probiotics applied in same manner
| Study group | Role | What they receive |
|---|---|---|
| Probiotic creme | Experimental | Women receing probiotic creme Receives: Device: probiotic creme |
| placebo | Placebo comparator | Women receiving a moisturizer Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of at least one LN bacteria strain in the intimate area of women in the intervention group
Bacterial Culture of LN bacterial strains
Measured: the end of a 10 days crème-usage
Secondary outcomes (2)
Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area
Measured by bacterial Culture and subtyping by PCR
Measured: at the end of creme usage and 10 days after finished crème-usage (9-11 days after).
subjective feeling of dryness and freshness in the intimate of women
Assessed through self adminstered questionnair with grading of feeling of dryness and freshness on a scale from 0 (no dryness and feeling fresh) to 5 (max dryness and absolutely not feeling fresh)
Measured: the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2014 (estimated)
- Study startSep 2013
- Primary completionMar 2014
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Menopausal Dryness in the Intimate Area of WomenStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Helena Kopp Kallner, Karolinska Institutet
- Investigators
- Helena Kopp Kallner, MD, PhD, Principal investigator, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02162160
- Sponsor's protocol ID
- KI DS 2013
- Status last verified
- Nov 2015
- First submitted
- 21 Nov 2013
- Last updated
- 26 Nov 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women
- ClinicalTrials.gov ID
- NCT02162160
- Acronym / sponsor ID
- KI DS 2013
- Keywords
- probiotic, post-menopausal, atrophic vaginitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Study start
- Sep 2013
- Primary completion
- Mar 2014 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 12 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before use of the crème and at the end of a 10 days crème-usage (day 8-10), as well as 10 days after (9-11 days) finished crème-usage.
The hypothesis is that lactobacilli can survive in the intimate area of postmenopausal women with use of a probiotic creme.
Detailed description
The rational for using probiotics is that the humans are colonized by a numbers of microorganisms from birth. These microorganisms are the natural flora of the human body. This bacterial ecology may be imbalanced due different circumstances: excessive hygiene, use of antibiotics or other drugs, use of alcohol, smoking, stress, diabetes and many other factors. The natural bacterial flora in the external part of the genital tract might be promoted by help of intimate products containing probiotics.
The study objectives Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before and at the end of a 10 days crème-usage (day 8-10), as well as 10 (9-11) days after finished crème-usage.
The primary endpoint of the study Presence of at least one LN bacteria strain in the intimate area of women in the intervention group compared to the intimate area of women in the control group at the end of a 10 days crème-usage (Day 8-10), as well as 10 (9-11) days after finished crème-usage. The primary endpint will be measured by bacterial Culture.
None-parametric statistical analyses.
Secondary endpoints Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).
Obtain information about the subjective feeling of dryness and freshness in the intimate of women before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).
Only descriptive statistics.
Blinding The active and comparative test product will be filled into white tubes with identical appearance.
The study will be conducted with double-blind design when neither the personnel at the clinic and the participants knows which product they are submitted/received. The study will also be blinded for the laboratory personnel analyzing the samples.
Randomization procedure The women will be randomly assigned to active or comparative test products. Based on a computer-generated list, before start of the study, nine tubes containing Probiotic Intimate Crème (the active product) and 9 tubes containing Soothing crème (the control product) will be randomly assigned to a number between 1 to 18, and the tubes labeled with the numbers. The numbered but otherwise visually identical tubes will delivered to the clinic before start of the study.
During the first visit, the participants will receive a tube consecutively in numerical order, as they are included in the study, i.e. according to their participant number.
The computer-generated randomization list and the product labeling will be carried out by people who don't have direct contact with the study participants.
Sample collection
Vaginal samples:
The samples will be taken by rolling sterile swabs over the upper third part of the lateral vaginal wall.
Labial samples:
For labial sampling, on the left side of the vulva near the vaginal orifice, the labia minor and major will be held apart and a sterile swab will be gently rubbed back and forth five times during rotation. The labial examination area will be approximately 2 cm2.
The swabs will then be placed in a prepared transport medium and sent to laboratory for analyses.
6.12. Study outline
Visit 1:
- Women visiting the clinic will be recruited to the study. After obtained information (Appendix 1) and signed informed consent the women will be clinically examined for any clinical symptoms of Candida vaginitis (ocular examination) and bacterial vaginosis (Amsel's criteria). The dryness of the mucus membranes will be also examined and the vaginal pH measured using a pH-stick.
- Women fulfilling the inclusion criteria will be randomized to 10 days use of test product (Probiotic Intimate Crème) or control product (Soothing Cream, ACO); 2 times daily, every morning and evening at bed time.
- The women will receive detailed instructions about how to use the study products.
- They will also asked to return the empty tube or remaining product at the end of study (Visit 3)
- The women will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale.
- Samples with sterile swabs will be collected from vagina, labia and perineum (Sample 1-L, Sample 1-V) and sent to an independent laboratory for analyses.
Visit 2:
- The 8th-10th day of the intimate crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH.
- They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
- Vaginal and labial swabs will be collected (Sample 2-L, Sample 2-V) and send to an independent laboratory for analyses.
Visit 3:
- 9-11 days after the 10 days crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH measured.
- They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
- Vaginal and labial swabs will be collected. (Sample 3-L, Sample 3-V) and sent to an independent laboratory for analyses.
During each visit, data will be recorded in the CRF.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Probiotic creme | Experimental | Device: probiotic cremeWomen receing probiotic creme |
| placebo | Placebo comparator | Drug: PlaceboWomen receiving a moisturizer |
Who may qualify
- Ages
- 45 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- healthy women 45-65 years old
- with subjective dryness in the intimate area
- postmenopausal with last menstruation more than or equal to 3 years prior to entering the study
- being willing to abstain sexual intercourse during the study period
Key exclusion criteria (4 listed)
- yeast infection or bacterial vaginosis
- use of antibiotics or antifungals
- use of estrogen
- participation in Another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| probiotic cremeAlso: Ellen ABProbiotic creme applied | Device | Probiotic creme |
| PlaceboCreme without probiotics applied in same manner | Drug | placebo |
Primary outcome
Presence of at least one LN bacteria strain in the intimate area of women in the intervention group
Time frame: the end of a 10 days crème-usage
Bacterial Culture of LN bacterial strains
2 secondary outcomes
Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area
Time frame: at the end of creme usage and 10 days after finished crème-usage (9-11 days after).
subjective feeling of dryness and freshness in the intimate of women
Time frame: the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2015.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helena Kopp Kallner, MD, PhD principal investigator
Karolinska Institutet
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing probiotic creme in people with Post Menopausal Dryness in the Intimate Area of Women, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of at least one LN bacteria strain in the intimate area of women in the intervention group (time frame: the end of a 10 days crème-usage). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2015.